- Home
- / Luoxin Pharmaceuticals Group
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Luoxin Pharmaceuticals Group financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
¥4.8
2024-10-29
Market Capitalization
¥4.9 B
2024-10-29
Revenue
¥2.2 B
FY, 2025
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| CNY | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.1B | 7.4B | 5.9B | 6.3B | 3.4B | 2.3B | 2.6B | 2.2B |
| Cost of goods sold | 1.9B | 2.8B | 2.8B | 3.2B | 2.6B | 1.3B | 1.5B | 1.1B |
| Gross profit | 4.2B | 4.7B | 3.2B | 3.2B | 918.7M | 1.1B | 1.1B | 1.1B |
| Gross profit margin, % | 63.4% | 53.9% | 50.5% | 26.8% | 46.5% | 42.2% | 50.2% | |
| Operating expense total | 3.6B | 3.8B | 2.5B | 2.4B | 2.2B | 1.3B | 1.3B | 1.1B |
| Depreciation and amortization | 123.6M | 154.8M | 170.7M | 186.3M | 215.7M | 214.8M | 419.1M | 229.8M |
| EBITDA | 607.9M | 885.1M | 670.8M | 808.6M | (1.3B) | (218.1M) | (216.6M) | (19.9M) |
| EBITDA margin, % | 11.9% | 11.3% | 12.8% | -38.1% | -9.5% | -8.4% | -0.9% | |
| EBIT | 518.1M | 756.9M | 445.3M | 581.6M | (1.5B) | (556.3M) | (892.1M) | (219.8M) |
| EBIT margin, % | 10.2% | 7.5% | 9.2% | -43.9% | -24.1% | -34.4% | -10.1% | |
| Interest income | 17.4M | 8.0M | 12.5M | 9.9M | 14.7M | 9.3M | 6.3M | 2.6M |
| Interest expense | 13.0M | 40.1M | 50.4M | 105.2M | 122.7M | 76.0M | 64.4M | 55.6M |
| Pre tax profit | 570.6M | 724.2M | 407.3M | 485.2M | (1.5B) | (604.1M) | (952.9M) | (290.9M) |
| Income tax expense | 45.7M | 70.5M | 66.3M | 63.6M | (205.0M) | 164.8M | 99.4M | (6.3M) |
| Net Income | 524.9M | 653.8M | 341.0M | 421.6M | (1.3B) | (768.9M) | (1.1B) | (284.5M) |